Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of KFA115 alone and with pembrolizumab in advanced cancers
jRCT2031230410Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of KFA115 in non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), cutaneous melanoma (CM) and 9 more (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of KFA115 as monotherapy and in combination with pembrolizumab. Started Jan 2024; status: active, not recruiting.
02
Drugs
KFA115
03
Conditions
non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)cutaneous melanoma (CM)High-Grade Serous Ovarian Cancer (HGSOC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on jRCT2031230410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230410.